Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the 12.4% return of the Russell 2000 Index ETF (IWM) and the 12.5% return for the Russell 2000 Value Index ETF (IWN). Year-to-date, the fund is up 4.9% net compared to 10.3% and 8.9% returns for the indexes, respectively. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2025.
In its third-quarter 2025 investor letter, Summers Value Partners highlighted stocks such as Journey Medical Corporation (NASDAQ:DERM). Journey Medical Corporation (NASDAQ:DERM) engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The one-month return of Journey Medical Corporation (NASDAQ:DERM) was 8.46%, and its shares gained 52.01% of their value over the last 52 weeks. On November 18, 2025, Journey Medical Corporation (NASDAQ:DERM) stock closed at $7.95 per share, with a market capitalization of $215.73 million.
Summers Value Partners stated the following regarding Journey Medical Corporation (NASDAQ:DERM) in its third quarter 2025 investor letter:
“Journey Medical develops and markets dermatology products. The company recently launched Emrosi for the treatment of rosacea. The rollout continues to be on track, with annualized sales approaching $30 million in the first six months following its launch. We believe Emrosi could exceed $100 million in peak sales based on positive physician and patient feedback. The company is positioned for profitability in 2026, supported by a scalable business model. Given ongoing consolidation in the dermatology industry, Journey may also be viewed as an attractive acquisition candidate. Our price target remains $20 per share.”
Journey Medical Corporation (NASDAQ:DERM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 4 hedge fund portfolios held Journey Medical Corporation (NASDAQ:DERM) at the end of the second quarter, compared to 6 in the previous quarter. Journey Medical Corporation’s (NASDAQ:DERM) revenue for the third quarter of 2025 was $17.6 million compared to $14.9 million in Q3 2024. While we acknowledge the potential of Journey Medical Corporation (NASDAQ:DERM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
finance.yahoo.com
#Journey #Medical #Corporation #DERM #Good #Investment
